What does spontaneous echo contrast ('smoke') on echocardiography indicate and how should it be managed?

Spontaneous Echo Contrast ("Smoke") on Echocardiography

Spontaneous echo contrast (SEC) on echocardiography indicates a prothrombotic state with blood stasis that mandates anticoagulation therapy, as it is an independent predictor of left atrial thrombus formation and thromboembolic events including stroke. 1

What SEC Represents

Spontaneous echo contrast appears as dynamic, swirling, smoke-like echoes within cardiac chambers—most commonly the left atrium (LA) or left atrial appendage (LAA)—and reflects red blood cell aggregation occurring under low-flow conditions. 2, 3 This phenomenon arises from interactions between erythrocytes and plasma proteins (particularly fibrinogen) at low shear rates, creating a hypercoagulable state that precedes frank thrombus formation. 3, 4

Clinical Conditions Associated with SEC

SEC occurs almost exclusively in specific cardiac conditions that promote blood stasis:

• Atrial fibrillation is the most frequent association, present in 95% of patients with SEC 5
• Mitral stenosis strongly predisposes to SEC formation, even when patients remain in sinus rhythm 6, 1
• Left atrial enlargement (M-mode diameter >50 mm or LA volume >60 mL/m²) creates the low-flow environment necessary for SEC 1
• Mitral valve prostheses are associated with SEC 5
• Notably, mitral regurgitation is protective against SEC formation due to increased flow velocities 5

Prognostic Significance and Risk Stratification

Dense or severe SEC is the strongest independent predictor of left atrial thrombus and subsequent embolic events, separate from the presence of atrial fibrillation itself. 2, 5

The thromboembolic risk correlates directly with SEC severity:

• In patients with nonvalvular atrial fibrillation, SEC predicts a 27-fold increased risk of stroke or peripheral embolism (95% CI: 2.7-267.8) 7
• SEC is present in almost all patients (95%) who have left atrial thrombus 3, 5
• SEC independently predicts cardiovascular death (OR = 7.63, p = 0.008) and when localized to the left atrium, predisposes to thromboembolism (OR = 10.15, p = 0.012) 8
• In patients with mitral stenosis or mitral valve replacement, SEC is the only independent predictor of left atrial thrombus or embolic events 5

Diagnostic Approach

Transesophageal echocardiography (TEE) is the gold-standard modality for detecting SEC, as transthoracic echocardiography rarely visualizes this finding. 2, 3 TEE provides superior visualization of the left atrial appendage (the most common site of thrombus formation) and allows quantification of SEC density and distribution. 2

Key TEE findings to assess:

• Presence and grade of SEC (see grading below)
• Left atrial appendage flow velocity (reduced velocity further stratifies risk) 2
• Exclusion of frank left atrial thrombus 1

Management: Anticoagulation Requirements

In Mitral Stenosis with SEC

Anticoagulation should be considered when TEE shows dense spontaneous echo contrast or an enlarged LA (M-mode diameter >50 mm or LA volume >60 mL/m²), even in patients with sinus rhythm (Class IIa recommendation, Level of evidence C). 6, 1

• Target INR: 2.0-3.0 (upper half of range preferred) 6, 9
• This recommendation applies even without prior embolism or documented thrombus 1
• Aspirin and other antiplatelet agents are not valid alternatives 6

In Atrial Fibrillation with SEC

Anticoagulation with vitamin K antagonist (VKA) targeting INR 2.0-3.0 is indicated in all patients with atrial fibrillation and SEC. 1, 9

• Patients with persistent atrial fibrillation should receive VKA treatment and not NOACs 1
• SEC serves as a marker to identify patients who benefit most from anticoagulation 3, 5

When Left Atrial Thrombus is Present

If SEC is accompanied by documented LA thrombus:

• Anticoagulation is mandatory (Class I recommendation, Level of evidence C) 1, 9
• When thrombus is located in the LA appendage and percutaneous mitral commissurotomy (PMC) is being considered, oral anticoagulation should be given for 2-6 months 6
• Repeat TEE must confirm thrombus resolution before proceeding with PMC 6, 1, 6
• If thrombus persists after anticoagulation, surgery is indicated 6, 1, 6

Special Considerations for Intervention

Contraindications to Percutaneous Mitral Commissurotomy

Left atrial thrombus is the most important contraindication to PMC. 6, 1, 6 However, the presence of dense SEC alone (without frank thrombus) is not an absolute contraindication but rather indicates:

• High thromboembolic risk requiring anticoagulation 1
• In asymptomatic patients with dense SEC, PMC should be considered only if they have favorable anatomical characteristics and the procedure is performed by experienced operators 1

Cardioversion Considerations

When SEC is present and cardioversion is planned:

• Minimum 3 weeks of therapeutic anticoagulation is required before cardioversion 2
• Anticoagulation must continue for at least 4 weeks after cardioversion due to atrial stunning and peak thromboembolic risk in the first 3 days post-procedure 2
• Cardioversion is not indicated before intervention in severe mitral stenosis, as it does not durably restore sinus rhythm 1

Common Pitfalls to Avoid

• Do not rely on transthoracic echocardiography alone to exclude SEC or thrombus; TEE is essential for adequate assessment 2, 3
• Do not substitute antiplatelet agents for anticoagulation when SEC is present—aspirin is not a valid alternative 6
• Do not proceed with PMC if LA thrombus is present without first achieving thrombus resolution with anticoagulation 6, 1, 6
• Distinguish SEC from true thrombus: SEC appears as swirling echoes without a discrete mass, while thrombus produces a well-defined echo-dense filling defect 2